Mikhail Blagosklonny attended the First Pavlov State Medical University of St. Peterburg and it was there that he formed the foundation of his expansive knowledge on the subject of cancer and aging. He received his M.D. in internal medicine and his PhD in experimental medicine and cardiology, both from the First Pavlov State Medical University of St. Peterburg. He quickly launched into his career and served as the associate professor of medicine at the New York Medical College, which is locate din Valhalla, New York. That was in 2002, and shortly afterward he was promoted to the senior scientists at the Ordway Research Institute in Albany, New York. He worked there for 5 years and then left to work at the Roswell Park Cancer Institute as their professor oncology. Read more about Mikhail at LinkedIn
He has done a large amount of research that focuses on narrowed cancer therapy that aim to protect the cells from damage. He is also interested in drugs that prevent aging and the aging process in general. Mikhail Blagosklonny is the editor in chief of several publications including Oncotarget, Cell Cycle, and Aging. He also works with the Cancer Biology & Therapy as their associate editor. Additionally, Mikhail Blagosklonny is on the editorial board as a member of the Cell Death & Differentiation. To this date, he has published over 250 journals and has thousands of citations which makes him well known in his industry.
Mikhail Blagosklonny recently released an abstract discussing drugs that are meant to prevent aging. Due to his discovery of the hyper function theory, Mikhail Blagosklonny released that aging was not caused by the buildup of random molecular damage. Rather, by using pathways that signal each other and target of rapamycin, that rapamycin is able to prevent diseases and treat the result of aging. In fact, these rapalogs can actually extend a human’s lifespan. This drug has the ability to target aging as well improve the effects that the human body endures while going through the aging process. That is not the only benefit that they have found to rapamycin, which was quickly and almost immediately accepted for clinical use. It will be able to help people who has cancer, autoimmune disorders, metabolic issues, heart disease, as well as general aging diseases.
Mikhail Blagosklonny also discussed what the proximal cause of aging was, based on the most recent research on the subject. The newest research, as stated above, supports a revolutionary theory that aging and disease are intricately linked. It is from this information that Mikhail Blagosklonny has come to think that is possible that ROS signaling plays a significant role in aging, disease, and cancer. He believes that using rapamycin can be used to increase the lifespan to the average healthy person. Rapamycin is typically used in cancer treatment but Mikhail Blagosklonny sees many more possibilities for it in the aging and anti aging world of the medical field. He passionately supports the use of rapamycin and hopes that more research will be conducted on it soon.